Minneapolis-based DiaMedica Therapeutics plans to conduct additional studies in order to resolve a clinical hold on its DM199 program for the treatment of acute ischemic stroke (AIS).
https://www.pharmalive.com/wp-content/uploads/2022/02/FDA-Action-Alert-Immunocore-Reata-CTI-Gilead-and-LegendJanssen-BioSpace-2-21-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-27 10:01:252022-10-27 10:01:25DiaMedica Ischemic Stroke Program Remains on Hold with Plans for Additional Studies
